Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.
Also called NCT05469659
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Sponsor
- Registry
-
NCT05469659 -
jRCTs031210339
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Japan
- Registry status
- Unknown status
Technical summary
Registry record NCT05469659. Randomized; no masking; primary purpose treatment. Start 2021-09-22 (actual); primary completion 2025-10-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)
- Acronym
- TRUTH-DKD
- Condition
- T2DM (Type 2 Diabetes Mellitus)
- Condition
- Metformin
- Condition
- SGLT2-Inhibitors (SGLT2 inhibitor)
- Intervention (Drug)
- Tofogliflozin
- Intervention (Drug)
- Metformin
- Lead sponsor
- Shinshu University
- Collaborator
- Kowa Company, Ltd.
Record details
- Record id
cardio:ct-nct05469659- Content hash
c45ff34f7f74f625e4690914cd9d02bc422573ff20b7cb23b8eac10be2fea270